Edesa Biotech Announces 2024 Annual General and Special Meeting on May 30

TL;DR

<b>Edesa Biotech will hold its 2024 Annual Meeting on May 30, 2024, to elect directors, approve executive compensation, and amend its equity incentive plan.</b>

AI Summary

Edesa Biotech, Inc. (EDSA) filed a Proxy Statement (DEF 14A) with the SEC on April 5, 2024. Edesa Biotech, Inc. will hold its 2024 Annual General and Special Meeting on May 30, 2024, at 10:30 a.m. local time. Shareholders will vote on the election of seven directors, advisory approval of executive compensation, and an amendment to the 2019 Equity Incentive Compensation Plan. The proposed amendment to the 2019 Plan seeks to increase the number of shares available for issuance by 67,000. MNP LLP is proposed for appointment as the Company's auditors for the fiscal year ending September 30, 2024. Shareholders of record as of April 2, 2024, are entitled to vote at the meeting.

Why It Matters

For investors and stakeholders tracking Edesa Biotech, Inc., this filing contains several important signals. The meeting will address key governance matters including director elections and executive compensation, impacting shareholder oversight. Shareholders will vote on increasing the share pool for the 2019 Equity Incentive Plan, potentially affecting future equity-based compensation and dilution.

Risk Assessment

Risk Level: low — Edesa Biotech, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual shareholder meeting and does not contain new financial or operational information that would indicate significant risk.

Analyst Insight

Shareholders should review the proposals regarding director elections, executive compensation, and the equity incentive plan amendment before the May 30th meeting.

Key Numbers

• 7 — Directors to be elected (Election of directors)
• 67,000 — Additional shares (Amendment to 2019 Equity Incentive Plan)
• May 30, 2024 — Meeting Date (2024 Annual General and Special Meeting)
• April 2, 2024 — Record Date (Shareholders eligible to vote)

Key Players & Entities

• Edesa Biotech, Inc. (company) — Registrant
• May 30, 2024 (date) — Date of Annual Meeting
• seven (dollar_amount) — Number of directors to be elected
• 2019 Equity Incentive Compensation Plan (company) — Plan to be amended
• 67,000 (dollar_amount) — Increase in shares for the 2019 Plan
• MNP LLP (company) — Proposed auditor
• September 30, 2024 (date) — Fiscal year end for auditor appointment
• April 2, 2024 (date) — Record date for voting eligibility

FAQ

Risk Factors

• Compliance with SEC Regulations [low — regulatory]: The company must comply with all SEC regulations regarding proxy solicitations and shareholder meetings.
• Shareholder Participation [low — operational]: Ensuring adequate shareholder participation and voting is crucial for the validity of decisions made at the meeting.
• Equity Incentive Plan Amendment [low — financial]: The proposed increase in shares for the 2019 Plan could impact future dilution and compensation costs.

Key Dates

• 2024-05-30: 2024 Annual General and Special Meeting — Shareholders will vote on key company matters.
• 2024-04-02: Record Date — Determines shareholders eligible to vote.
• 2024-05-28: RSVP Deadline — Deadline to RSVP for in-person attendance.

Filing Documents

• edsa_def14a.htm (DEF 14A) — 535KB
• edsa_def14aimg1.jpg (GRAPHIC) — 158KB
• edsa_def14aimg2.jpg (GRAPHIC) — 164KB
• 0001654954-24-004307.txt (&nbsp;) — 980KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 15 Summary Compensation Table 15 Employment and Change in Control Agreements 16 Outstanding Equity Awards at September 30, 2023 23 PAY VERSUS PERFORMANCE 24 DIRECTOR COMPENSATION 26 EQUITY COMPENSATION PLAN INFORMATION 27 REPORT OF THE AUDIT COMMITTEE 29

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 30 TRANSACTIONS WITH RELATED PERSONS 32 PROPOSAL 2 34 PROPOSAL 3 35 PROPOSAL 4 45 SHAREHOLDER PROPOSALS 47 ANNUAL REPORT 47 HOUSEHOLDING OF ANNUAL MEETING MATERIALS 48 OTHER MATTERS 48 APPENDIX A App-1 Table of Contents EDESA BIOTECH, INC. 100 Spy Court, Markham, ON Canada L3R 5H6 PROXY STATEMENT General Information Concerning Voting and Solicitation This proxy statement is being furnished to you in connection with the solicitation by the Board of Directors (the "Board") of Edesa Biotech, Inc., a British Columbia corporation ("we", "us", "Edesa", or the "Company"), of proxies in the accompanying form to be used at the 2024 Annual General and Special Meeting of Shareholders of the Company to be held at the Edesa Biotech Corporate Offices, located at 100 Spy Court, Markham, ON Canada L3R 5H6 at 10:30 a.m. (local time) on Thursday, May 30, 2024, and at any adjournments or postponements thereof (the "Annual Meeting"). As a British Columbia corporation subject to the reporting requirements of the U.S. Securities and Exchange Commission, our proxy disclosure has been prepared to comply with U.S. proxy disclosure requirements as allowed under National Instrument 51-102F6. Our Board has fixed April 2, 2024 as the record date for determining those shareholders entitled to receive notice of, and to vote at, the Annual Meeting. Only shareholders of record at the close of business on April 2, 2024 will be entitled to vote at the Annual Meeting. These materials are first being sent or given to the shareholders on or about April 16, 2024. This proxy statement gives you information on the proposals to be presented at the Annual Meeting so that you can make an informed decision. Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting To Be Held on May 30, 2024. Our proxy materials including the Proxy Statement for the Annual Meeting, our

View Full Filing

View this DEF 14A filing on SEC EDGAR